Expanding Treatment Options for Newly Diagnosed Multiple Myeloma: Proteasome Inhibitors, Immunomodulatory Drugs, and Other Targeted Therapies

Please Log In or Register to continue.

Release Date: September 27, 2017
Expiration Date: September 27, 2018

Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

In recent years, advances in treatment have resulted in significantly improved outcomes and prognoses in patients with multiple myeloma; much of this research, however, was focused on the population of patients with relapsed or refractory disease. Today, a growing compendium of data and ongoing research is evaluating treatment options and management approaches specifically in patients with newly diagnosed multiple myeloma. Topics being evaluated include: when to treat smoldering versus symptomatic myeloma; factors to consider when selecting an induction regimen from among the current standard of care to new options investigated in the clinical trial setting; and the role of high-dose therapy consolidation and maintenance therapy. In this activity, Dr. Lonial summarizes the current state of research in each of these areas, and discusses the potential impact of the application of this information on improving outcomes and progression-free survival in patients with newly diagnosed multiple myeloma.

Target Audience

This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills in multiple myeloma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe the unmet need that exists in current treatment paradigms for patients with newly diagnosed multiple myeloma (NDMM)
  • Identify novel therapies and drug regimens under investigation for patients with NDMM including proteasome inhibitors and immunomodulatory drugs
  • Summarize clinical trials with current or planned recruitment that are investigating novel therapies in NDMM

Agenda

Expanding Treatment Options for Newly Diagnosed Multiple Myeloma: Proteasome Inhibitors, Immunomodulatory Drugs, and Other Targeted Therapies – Sagar Lonial, MD, FACP

Instructions for Participation and Credit

This activity is eligible for credit through September 27, 2018. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Dr. Sagar Lonial earned his medical degree from the University of Louisville School of Medicine. He completed his internship and residency at Baylor College of Medicine in Houston, Texas, followed by a fellowship in hematology/oncology at Emory University School of Medicine in Atlanta, Georgia. He is the Department Chair for Hematology and Medical Oncology at Emory University.

Dr. Lonial serves as Vice Chair of the Myeloma Committee in the Eastern Cooperative Oncology Group and as Chair of the Steering Committee for the Multiple Myeloma Research Consortium. Additionally, he is on the Board of Directors for the International Myeloma Society and on the Scientific Advisory Board for the International Myeloma Foundation. Dr. Lonial is the myeloma editor for Clinical Lymphoma and Myeloma and is on the editorial board for the Journal of Clinical Oncology. He is also an ad hoc reviewer for Blood, Cancer Research, Clinical Cancer Research, Haematologica, Leukemia, and other journals, and has authored or co-authored over 200 papers and abstracts.

Dr. Lonial has worked in the field of immunotherapy and cancer, and has spent time developing the B-cell malignancy program with respect to novel targeted agents in laboratory models as well as early clinical trials. His previous laboratory work has focused on evaluating the impact of purified dendritic cell subsets on the nature of immune responses against antigen. Most recently, Dr. Lonial has focused on combinations of novel agents as therapy for myeloma and lymphoma, particularly evaluating combinations that may result in synergistic inhibition of the PI3-K/Akt pathway and the role of 14-3-3 in proteasome function.

Accreditation

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-17-164-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Sagar Lonial has received honoraria related to formal advisory activities from Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novartis AG, and Takeda Oncology. He has received grant support related to research activities from Bristol-Myers Squibb, Celgene, and Takeda Oncology.

Planning Committee Disclosures

The individual listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at lisa@medicaled.com

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Takeda Oncology.

©2017 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

Please Log In or Register to continue.